- 14 March
-
At the end of the last year, Novouralsk-based Medsintez Plant turned 20 years old. Alexander Petrov, Chairman of the plant's Board of Directors, told Regions of Russia about the impressive successes that the company has achieved over the years and its ambitious plans for the future.
- 22 January
-
In 2023, the Medsintez Plant, in collaboration with the Promomed Group of Companies, launched the production of a full cycle of hypoglycemic drugs Enligria (liraglutide) and Quincenta (semaglutide) used in treating type II diabetes mellitus, including in patients with obesity and overweight or cardiovascular disease. The preparations are available in the most convenient and familiar for patients dosage form – a disposable prefilled injection and have already been supplied to pharmacies.
- 13 December
-
Medsintez Plant LLC presented the latest biotechnological developments of pharmaceuticals at the largest international scientific and practical forum in the field of medicine and health care Russian Health Care Week — 2023 held from December 4 to December 8 in Moscow. The main purpose of the Forum is to facilitate the implementation of the national projects “Healthcare” and “Demography”, “Tourism and Hospitality Industry”, the federal project “Development of Medical Services Export”, as well as summarizing the results of the Year of Science and Technology in Medicine.
- 04 October
-
On September 27, as part of the business program of the GMP conference with international participation, Alexander Petrov, Chairman of the Board of Directors of Medsintez Plant LLC, took part in a Plenary Session on the issues of regulating the circulation of medicines in Russia and the EAEU, developing import independence, and increasing export potential. The session was attended by representatives of the Ministry of Industry and Trade of the Russian Federation, the Minister of Health of the Republic of Nicaragua, the WHO Representative in Russia, a Representative of the Serbian Ministry of Health and other Russian and foreign experts. Mr. Petrov spoke about the problems that Russian pharmaceutical companies face when entering international markets and suggested possible solutions.
- Home
- Cluster members
- URAL NANOTECHNOLOGY CENTER, LLC
URAL NANOTECHNOLOGY CENTER, LLC
URAL NANOTECHNOLOGY CENTER, LLC is a developer and manufacturer of unique innovative products under DEZITOL trademark.
The main activity of the company is production of high quality products based on unique innovative solutions for the Russian and international markets. DEZITOL products are designed to protect against transmission and development of infections, and are successfully used in various areas with higher sanitary requirements, such as medicine and agriculture, and others. Currently, DEZITOL product line includes
Disinfectant (skin antiseptic) DEZITOL A
Skin antiseptic based on isopropyl alcohol for hand treatment, including hands of surgeons, operating field, injection field, gloves on the hands of medical personnel (in accordance with the instructions for use). Having high antimicrobial activity, it is gentle for skin. Effective against pathogens of healthcare-associated infections and Mycobacterium tuberculosis (tested on Mycobacterium terrae).
Passed tests at Disinfectology Research Institute of the Federal Service for the Oversight of Consumer Protection and Welfare.
Effective against pathogens of healthcare-associated infections and Mycobacterium tuberculosis (tested on Mycobacterium terrae).
It is intended for hygienic treatment of hands of personnel at industrial enterprises, catering facilities, municipal facilities, sanitary inspection checkpoints, hairdressing salons, beauty salons, etc.
In accordance with the letter of the Federal Budgetary Institution of Science Disinfectology Research Institute of the Federal Service for the Oversight of Consumer Protection and Welfare ref. No. 77-53-02/468-2020.1.15 dated April 23, 2020, formula of the skin antiseptic DEZITOL A allows application thereof to prevent coronavirus COVID-19 and other viral infections.
Antimicrobial preventive coating DEZITOL B
Innovative product for long- term antimicrobial skin protection. The use thereof in surgical hospitals allows for multi- barrier protection of a patient against pathogenic microflora during operative time and postoperative periods.
DEZITOL B is used on operative field to create a protective incise drape, as well as to close the postoperative wound, to increase comfort of the patient's stay in the hospital due to a possibility of non- dressing treatment of the postoperative wound.
Also, this product is actively used by the population in everyday life as a «Liquid bandage» to close small scratches, small superficial and postoperative wounds, preventing bedsores up to the stage II, protecting the skin around fistulas and stoma.
Protective coating DEZITOL C
A unique development of the Urals scientists — a coating with no analogues in the world. Designed to create a protective coating on surrounding surfaces with a long-lasting antimicrobial effect (up to 12 months).
All products have passed the required tests and are registered. Protective coating DEZITOL C successfully confirmed the declared characteristics in independent accredited laboratories of the European Union countries and the Arab Republic of Egypt.
Currently, the manufactured products have successfully passed long-term full-scale tests and are actively used in medical institutions of the Russian Federation.
Production technology of DEZITOL products is fully automated and complies with GOST ISO 13485-2017 “International Standard. Medical products. Quality management systems. Requirements for Regulatory Purposes” and ISO 9001:2015 “Quality Management Systems. Requirements".
Tel. 8-800-775-52-55 (within Russia calls are free)
E-mail: info@dezitall.ru
